Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Athanasia Skoura"'
Autor:
Muhammad Ali, MD, Benjamin Pulli, MD, Gabriel Courties, PhD, Benoit Tricot, MSc, Matthew Sebas, BSc, Yoshiko Iwamoto, BSc, Ingo Hilgendorf, MD, Stefan Schob, MD, Anping Dong, MD, PhD, Wei Zheng, MD, Athanasia Skoura, PhD, Amit Kalgukar, PhD, Christian Cortes, MSc, Roger Ruggeri, PhD, Filip K. Swirski, PhD, Matthias Nahrendorf, MD, PhD, Leonard Buckbinder, PhD, John W. Chen, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 1, Iss 7, Pp 633-643 (2016)
PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ven
Externí odkaz:
https://doaj.org/article/5d384185ad4c40cb8317d9fa9493cf98
Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function.
Autor:
Sebastian Albinsson, Athanasia Skoura, Jun Yu, Annarita DiLorenzo, Carlos Fernández-Hernando, Stefan Offermanns, Joseph M Miano, William C Sessa
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e18869 (2011)
Phenotypic modulation of smooth muscle cells (SMCs) plays a key role in vascular disease, including atherosclerosis. Several transcription factors have been suggested to regulate phenotypic modulation of SMCs but the decisive mechanisms remain unknow
Externí odkaz:
https://doaj.org/article/a7f8cc5ef7964823a03ac017e0158e83
Autor:
Athanasia Skoura, Timothy Hla
Publikováno v:
Journal of Lipid Research, Vol 50, Iss , Pp S293-S298 (2009)
Lysophospholipid (LP) research has experienced a period of renaissance with the discovery of the lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) receptors in the late 1990s. Vertebrate LP receptors regulate embryogenesis, vascular devel
Externí odkaz:
https://doaj.org/article/7e14ce570b95474eba49fe0c1d331070
Autor:
Andrzej J. Jakubowiak, Nizar J. Bahlis, Noopur S. Raje, Caitlin Costello, Bhagirathbhai R. Dholaria, Melhem M. Solh, Moshe Y. Levy, Michael H Tomasson, Harman Dube, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward Michael Chan, Suzanne Trudel, Michael P Chu, Cristina J. Gasparetto, Andrew Peter Dalovisio, Michael Sebag, Alexander M. Lesokhin
Publikováno v:
Journal of Clinical Oncology. 40:8014-8014
8014 Background: Elranatamab (PF-06863135) is a bispecific molecule that activates and redirects the T-cell mediated immune response against multiple myeloma (MM), a plasma cell dyscrasia characterized by expression of B-cell maturation antigen (BCMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7364a6a6a7e878bab31990bb41feb780
https://doi.org/10.1200/jco.2022.40.16_suppl.8014
https://doi.org/10.1200/jco.2022.40.16_suppl.8014
Autor:
Michael P. Chu, Michael Damore, Noopur Raje, Hoi Kei Lon, Cynthia Basu, Nizar J. Bahlis, Cristina Gasparetto, Michael Sebag, Caitlin Costello, Bhagirathbhai Dholaria, Suzanne Trudel, Harman Dube, Melhem Solh, Andrew Dalovisio, Athanasia Skoura, Moshe Yair Levy, Andrzej Jakubowiak, Michael H. Tomasson, Alexander M. Lesokhin, Edward Chan
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S195-S196 (2021)
Objectives Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor superfamily expressed in multiple myeloma, and CD3 on T cells. We reported results for intrav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579f0fee7dd908721e3ee7f35b33920c
https://doi.org/10.1016/j.htct.2021.10.331
https://doi.org/10.1016/j.htct.2021.10.331
Autor:
Moshe Yair Levy, Andrzej Jakubowiak, Harman Dube, Melhem Solh, Bhagirathbhai Dholaria, Nizar J. Bahlis, Michael Damore, Michael H. Tomasson, Caitlin Costello, Edward Chan, Alexander M. Lesokhin, Athanasia Skoura, Cristina Gasparetto, Andrew P. Dalovisio, Noopur Raje, Michael Sebag, Hoi Ken Lon, Suzanne Trudel, Michael P. Chu, Cynthia Basu
Publikováno v:
Blood. 138:895-895
Introduction: MagnetisMM-1 (NCT03269136) is a Phase 1 study of elranatamab (PF-06863135), a humanized bispecific molecule that targets BCMA expressed on multiple myeloma (MM) and engages CD3 on T cells, for patients (pts) with relapsed or refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::081d845f232f1ef999afee1dc5a3b2dc
https://doi.org/10.1182/blood-2021-150519
https://doi.org/10.1182/blood-2021-150519
Autor:
Hoi Kei Lon, Bhagirathbhai Dholaria, Suzanne Trudel, Michael Sebag, Michael Damore, Cristina Gasparetto, Andrzej Jakubowiak, Michael H. Tomasson, Nizar J. Bahlis, Edward Chan, Harman Dube, Michael Chu, Andrew P. Dalovisio, Caitlin Costello, Cynthia Basu, Athanasia Skoura, Noopur Raje, Moshe Yair Levy, Alexander M. Lesokhin, Melhem Solh
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S17
Background Elranatamab (PF-06863135), a humanized bispecific molecule, targets both BCMA expressed in MM and CD3 on T cells. MagnetisMM-1 (ClinicalTrials.gov ID: NCT03269136) is a Phase 1 study of elranatamab with the aim of characterizing the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c7048def364329190bfc78607ce332e
https://doi.org/10.1016/s2152-2650(21)02100-5
https://doi.org/10.1016/s2152-2650(21)02100-5
Autor:
Moshe Levy, Nizar Bahlis, Noopur Raje, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Michael Tomasson, Harman Dube, Michael Damore, Hoi Kei Lon, Cynthia Basu, Athanasia Skoura, Edward Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael Chu, Cristina Gasparetto, Andrew Dalovisio, Michael Sebag, Alexander Lesokhin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S252
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9787ce36a56d2914febc77e078531dad
https://doi.org/10.1016/s2152-2650(21)01578-0
https://doi.org/10.1016/s2152-2650(21)01578-0
Autor:
Bhagirathbhai Dholaria, Michael Chu, Andrew P. Dalovisio, Cynthia Basu, Hoi Kei Lon, Alexander M. Lesokhin, Andrzej Jakubowiak, Suzanne Trudel, Noopur Raje, Moshe Yair Levy, Cristina Gasparetto, Athanasia Skoura, Harman Dube, Michael Sebag, Michael Damore, Melhem Solh, Nizar J. Bahlis, Caitlin Costello, Michael H. Tomasson, Edward Chan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S439
Context Elranatamab (PF-06863135), a humanized bispecific monoclonal antibody (IgG2a), targets BCMA expressed in MM and CD3 on T-cells. Objective Characterize efficacy, safety, pharmacokinetics, and pharmacodynamics of elranatamab. Design Phase 1 stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d0ee92cd63cc1798cae312ff153c11c
https://doi.org/10.1016/s2152-2650(21)01978-9
https://doi.org/10.1016/s2152-2650(21)01978-9
Autor:
Ingo Hilgendorf, Filip K. Swirski, Amit Kalgukar, Leonard Buckbinder, Roger B. Ruggeri, Stefan Schob, John W. Chen, Matthew Sebas, Benoit Tricot, Yoshiko Iwamoto, Christian Cortes, Benjamin Pulli, Gabriel Courties, Anping Dong, Wei Zheng, Athanasia Skoura, Muhammad Ali, Matthias Nahrendorf
Publikováno v:
JACC: Basic to Translational Science, Vol 1, Iss 7, Pp 633-643 (2016)
JACC: Basic to Translational Science
JACC: Basic to Translational Science
Visual Abstract
Highlights • The inflammatory enzyme MPO is a potential therapeutic target in cardiovascular diseases. • PF-1355 is an orally bioavailable mechanism-based inhibitor of MPO enzymatic activity. PF-1355 treatment successfully in
Highlights • The inflammatory enzyme MPO is a potential therapeutic target in cardiovascular diseases. • PF-1355 is an orally bioavailable mechanism-based inhibitor of MPO enzymatic activity. PF-1355 treatment successfully in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f865d2b9a48e7c50f62499fffc36ea2c
https://doi.org/10.1016/j.jacbts.2016.09.004
https://doi.org/10.1016/j.jacbts.2016.09.004